A Case Control Study of Resveratrol Effects in Coronary Artery Disease Patients With Metabolic Syndrome

Coronary Artery Disease Clinical Trial

Official title:

Effects of Resveratrol on Crosstalk Between Canonical β-catenin/Wnt and FOXO Pathways in Coronary Artery Disease Patients With Metabolic Syndrome: A Case Control Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02137421
• Other study ID #: 17001-30-01-91
• Status: Completed
• Phase: N/A
• First received: May 9, 2014
• Last updated: April 30, 2017
• Start date: April 2012
• Est. completion date: December 2014

Study information

• Verified date: May 2014
• Source: Tehran University of Medical Sciences
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this study is to explore the role of Canonical β-catenin/Wnt and forkhead box O (FOXO) pathways by means of investigating their target genes in coronary artery disease (CAD) pathogenesis and to examine the effects of resveratrol (RES) on these pathways in CAD patients.

Description:

Metabolic syndrome is a constellation of cardiovascular and metabolic risk factors including obesity, insulin resistance, hypertension and dyslipidemia. Coronary artery disease (CAD) is considerably linked with these risk factors. Oxidative stress has a major role in development of atherosclerosis that is believed as the most common pathologic process underlying CAD. The up-regulated gene-expression of free radical scavenging enzymes such as manganese superoxide dismutase (MnSOD) by members of the forkhead box O (FOXO) transcription factors is considered to be one of the paramount cell defensive mechanisms against oxidative damage. It is now well recognized that β-catenin binds to FOXOs during oxidative stress and acts as the pivotal mediator in canonical Wnt signaling, so that it translocates to the nucleus and interacts with the family of transcription factors T-cell factor/lymphoid enhancer factor (TCF/LEF), to regulate the expression of Wnt target genes. Recent evidence suggested that the canonical Wnt signaling plays a profound role in regulation of lipid metabolism and glucose homeostasis. Peroxisome proliferator-activated receptor delta (PPAR-δ) is one of the Wnt target genes which is believed to be operative in cardiometabolic protection. Interestingly, it has been demonstrated that impaired Wnt signaling pathway is contributed to inflammation, foam cell formation, and endothelial dysfunction which are recognized as atherosclerosis pathogenic factors. Resveratrol (RES) (3, 4´, 5 trihydroxystilbene), a natural polyphenol with antioxidant effects can be found in red grapes and its processed drinks (e.g. red wine), peanuts, pomegranates and mulberries.Increasing body of evidence suggest a protective role for RES against CAD, however the underlying mechanisms still remain to be elucidated. We perform this study on 10 metabolic syndrome patients with three-vessel CAD and 10 sex-aged matched (men with 40-55 years old) healthy subjects as controls. The effects of RES on β-Catenin, manganese superoxide dismutase (MnSOD), and peroxisome proliferator-activated receptor delta (PPAR-δ) expression are evaluated in peripheral blood mononuclear cells (PBMCs) of participants.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: December 2014
• Est. primary completion date: August 2014
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 40 Years to 55 Years

Eligibility

Inclusion Criteria:

-Three vessel coronary artery disease with metabolic syndrome based on WHO criteria

Exclusion Criteria:

• Malignancy,

• Myocardial infarction,

• Unstable angina,

• Previous coronary intervention,

• Inflammatory diseases,

• Diabetes,

• Hypertension,

• Endocrine disorders,

• Other known chronic diseases,

• Antioxidant therapy or vitamin supplements in the previous 12 months,

• Smokers .

Related Conditions & MeSH terms

• Coronary Artery Disease
• Coronary Disease
• Metabolic Syndrome
• Metabolic Syndrome X
• Myocardial Ischemia
• Syndrome

Intervention

Dietary Supplement:
• Resveratrol (3, 4´, 5 trihydroxystilbene)
Resveratrol (RES) (3, 4´, 5 trihydroxystilbene)

Locations

Country	Name	City	State
Iran, Islamic Republic of	Islamic Republic of Iran	Tehran

Sponsors (1)

Lead Sponsor	Collaborator
Tehran University of Medical Sciences

Country where clinical trial is conducted

Iran, Islamic Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	PBMCs viability assay by MTT ( 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide ) test .		Change from baseline after 12 and 24-hour treatment with resveratrol
Primary	Relative gene expression by real-time PCR (polymerase chain reaction)	PBMCs (2×106/well) are seeded in 96-well plates and undergo overnight incubation in humidified atmosphere at 37° C temperature with 5% CO2(carbon dioxide), then the medium is removed by centrifugation at 300g for 15 min and replaced with a fresh medium containing 50 micromolar resveratrol (dissolved in DMSO (Dimethyl sulfoxide)) for 12 hours. Then, RNA extraction, cDNA(complementary DNA) synthesis and real-time PCR are performed for ß-catenin, MnSOD, and PPAR-delta genes .	Change from baseline after 12-hour treatment with resveratrol
Secondary	MnSOD enzyme activity assay .		Change from baseline after 12-hour treatment with resveratrol
Secondary	Total ß-catenin protein measurement		Change from baseline after 12-hour treatment with resveratrol